SynthesisJournal of neurology2026
Genetic correlates of corticobasal degeneration: a systematic review and meta-analysis.
Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCorticobasal degeneration (CBD) is a primary 4-repeat tauopathy marked by progressive motor, cognitive, and behavioral decline, substantial clinicopathologic heterogeneity, and few disease-modifying therapeutic options. Although MAPT variation has long been implicated in CBD susceptibility, the full genetic architecture of CBD has remained highly fragmented and poorly synthesized.
methodsThis systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines to identify studies evaluating genetic associations with CBD through August 2026. Eligible studies reported effect estimates for MAPT haplotypes, MAPT subhaplotypes, MAPT SNPs, or non-MAPT candidate loci. Risk of bias was assessed using ROBINS-E, and pooled associations were calculated using inverse-variance meta-analysis. Twenty-two studies published between 2001 and 2025 were included.
resultsThe most consistent associations involved MAPT haplotype architecture, with H1 and H1/H1 showing increased CBD susceptibility and H2 showing a protective association. Among MAPT H1 subhaplotypes, H1c, H1d, and H1q demonstrated significant risk associations, whereas other subhaplotypes showed less significant effects. MAPT SNP-level associations were generally modest, though several variants showed small yet significant protective or risk-related effects. Among non-MAPT loci, C9orf72, MOBP, and KIF13B were associated with CBD risk.
conclusionsThese results indicate that genetic susceptibility to CBD is dominated by MAPT architecture; however, significant heterogeneity within and beyond MAPT exists, with significant contributions from select subhaplotypes, SNPs, and non-MAPT loci. Overall, these findings support tau-centered genetic vulnerability while highlighting candidate pathways relevant to CBD pathogenesis, glial biology, and broader neurodegenerative vulnerability, providing a foundation for future biomarker, mechanistic, and precision-medicine studies.
Indexed as
Identifiers
42891694What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.